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infrarenal AAA repair, exposing susceptible patients to an
increased risk of paraplegia after subsequent TAAA repair.
Our operative approach to these patients is individual-
ized, but it generally parallels our initial strategy within that
Crawford class. Segmental cross-clamping with distal per-
fusion is the norm for replacement of the residual aorta. If
the original procedure was performed by way of a retroper-
itoneal approach, the remedial procedure is performed by
way of a transabdominal thoracoabdominal incision to
avoid the scarred retroperitoneal dissection. Early in our
experience we did not use lumbar drains; however, we now
prefer to place lumbar drains for all patients with recurrent
TAAA to optimize spinal cord protection, because the
remedial procedure usually results in total thoracoabdomi-
nal aortic replacement.
Patients who present with Crawford patch aneurysms
are converted from inclusion technique to separate bypasses
to each vessel in the degenerated patch (octopus grafts). We
now prefer to use profound hypothermic circulatory arrest in
these latter cases, because it provides additional visceral and
renal protection during individual reconstruction of the vis-
ceral and renal vessels. Dardik et al16,17 described a series of
229 patients in which 8 patients presented with visceral patch
expansion related to connective tissue disorders. Although
patients with Marfan syndrome comprised only 4% of our total
study population, these patients accounted for 25% of all
reoperations for failed prior TAAA and one third of our
reoperations for Crawford patch aneurysm.
CONCLUSIONS
Patients remain at risk of further degeneration of the
residual aorta after TAAA repair, mandating careful patient
surveillance. Patients with Marfan syndrome represent a
disproportionate number of the patients with failed prior
TAAA repair. Reoperative aortic replacement for TAAA is
more likely to incur postoperative complications than initial
surgery for TAAA, particularly in patients with prior AAA
repair, but mortality is not significantly increased. Special
technical considerations exist for these challenging pa-
tients, requiring adjunctive measures for renal, visceral, and
spinal cord protection. Patients with failed TAAA proce-
dures or progression of aneurysmal extent can be offered
reoperation with acceptable results.
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DISCUSSION
Dr Gregorio A. Sicard (St Louis, Mo). It is an honor and a
pleasure to be here with you today and also to discuss this excellent
paper that Dr Lombardi just presented. As we all know, thoraco-
abdominal aneurysm surgery still remains primarily an open surgi-
cal procedure, especially with involvement of the visceral and renal
components of it. Although endoluminal treatment of thoracic
aneurysms is growing and will have a significant impact, there are
still a lot of challenges that remain with the use of this new
technology in the visceral and renal area.
I think these results are superb and are extremely comparable
with larger series from centers like Houston—both Baylor and
now Safi’s experience at the University of Texas. A mortality rate of
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11% in these difficult patients with a paraplegia rate of 3.6% is
outstanding. I had the pleasure of having the paper about a week
ago, so I could read and dissect it a little bit. But I was surprised to
find out that only 36% of patients in this entire series of 279
patients had cerebrospinal fluid drainage and only 50% had the
adjunct of left heart bypass. Despite this, if you look at the number
of patients who had type I and type II thoracoabdominal aneu-
rysm, the patients whom we all recognize as having a higher risk for
paraplegia and other significant complications, the paraplegia rate
in that group was only 3%. This is outstanding. But I do have a
couple of questions for Dr. Lombardi.
Since 80% of your patients in your entire series are type I, type
II and type III, and you only use cerebrospinal fluid drainage as an
adjunct in 36% and the Bio-Medicus pump in about 49% of the
patients, did you use any adjuncts in the other group and, if so,
what kind? And if you are able to obtain a paraplegia rate of 3% in
type I and type II, and only use cerebrospinal fluid drainage in 36%
and the Bio-Medicus pump in 50%, do we really need the drain?
I think that Safi presented a wonderful paper at the American
Surgical Association last week, with over 1,000 cases in a 10-year
period, in which he showed that this adjunct has made a difference.
But the paraplegia rate without adjuncts was almost 3 times as high
as yours. So what are the tricks of the trade that you could share
with us to tell us how to get these outstanding results? In our
experience, using the adjunct of cerebrospinal fluid drainage and
Bio-Medicus pump, we have significantly decreased the number of
complications, including renal failure and paraplegia. But one
thing that we have not been able to resolve is that half of our cases
of paraplegias are delayed paraplegias; in other words, paraplegia
rates that have occurred from 24 to 30 months later after the
procedure. Could you comment on that? Have you seen this
complication? And does the use of all these adjuncts diminish the
intraoperative or immediately postoperative paraplegia rate, but
not alter the potential paraplegia or paraparesis rates in people who
could develop hypotension or respiratory problems?
How has the increasing use of endoluminal grafts changed
your approach to the treatment of these redo operations? In other
words, do you look for other alternatives to open surgery in, for
example, a patient that may develop an intercostal patch aneurysm?
I think the Hopkins group has published excellent results. These
patients are living longer. And if we do big patches and they live
longer, they will come back with aneurysms in this sector. So are
there any endoluminal tricks that can be used, short of a big
operation? We find that pulmonary complications in redo thoraco-
abdominal surgery is significant because of the extensive, difficult
dissection of the lung. So I’d like you to comment on this.
And lastly, it is obvious that dissection—and, more specifically,
Marfan’s syndrome—has a significant recurrence rate of dilata-
tions. Have you changed your approach now to the visceral patch
and renal reconstruction? Should we be doing isolated limbs from
the main graft to each one of the individual vessels, visceral and
renal, to avoid the potential dilatation? Have you changed your
approach on the basis of your results?
Thank you. This is a real landmark paper on a very difficult
technical problem.
Dr Joseph Lombardi. Thank you, Dr Sicard. With regard to
the patients who had CFS drains and atriofemoral bypass, this is
over a 10-year period and early in our experience we didn’t employ
these adjuncts.
As to how they explain the low incidence of paraplegia, I don’t
have a great answer for that. I believe we did look at our early
paraplegia rate versus our late paraplegia rate, and there was a slight
skew of patients more toward the earlier experience than the later
experience; however, this wasn’t significantly different.
With respect to the patients with delayed paraplegia, we have
seen this in the intensive care units; and we are very thankful that
we placed CSF drains preoperatively, because once you augment
their systemic arterial pressure and also start resuming cerebrospi-
nal fluid drainage, you see that their neurologic deficits disappear.
This is anecdotal and I’ve seen it in only a handful of patients this
year; however, this is a significant advancement in the adjuncts with
respect to paraplegia.
As far as stent-graft technology, I certainly believe this is a
subgroup of patients that we can help most. I think this is the type
of case in which you want to try and maximize the utility of
technology such as the fenestrated and also branched stent grafts
that Tim Chuter put together. Although we have demonstrated
pretty low mortality associated with redo procedures, I think this is
a target population for endoluminal grafting.
And lastly, with respect to the Marfan’s syndrome patients, I,
myself, after reviewing this data and the Hopkins group’s data,
would think twice about the size of the patch that I place. I think
now we may entertain the thought of a separate bypass graft or
limbs for individual visceral vessels given the high incidence of
patch expansion in this population.
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